Protara Therapeutics Presents Groundbreaking Insights from THRIVE-1 Study on Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support at ESPEN Conference’
NEW YORK, Sept. 09, 2024 - Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company at the forefront of developing transformative therapies for cancer and rare diseases, has unveiled key findings from its THRIVE-1 study. This prospective, observational study investigated the prevalence of choline deficiency and liver injury in patients dependent on parenteral support (PS). These promising results were presented during a poster session at the 46th European Society for Clinical Nutrition and Metabolism Congress (ESPEN), held from September 7, 2024, to September 10, 2024, in Milan.
Choline, an essential nutrient, plays crucial roles in a variety of bodily functions including liver health, brain development, and muscle movement. Deficiency in choline has been linked to liver disease, muscle damage, and other serious health issues. Given its significance, understanding the prevalence of choline deficiency in patients reliant on parenteral support those who receive their nutrition intravenously could pave the way for enhanced therapeutic interventions.
Results from THRIVE-1 underscore the critical need for routine monitoring and supplementation of choline in patients on parenteral support. The study revealed a notable prevalence of choline deficiency and associated liver injury, indicating that supplementary choline could potentially mitigate these adverse health effects. Dr. Janet Clark, Principal Investigator of the study, commented, Our findings highlight an urgent need for healthcare providers to reconsider current nutritional guidelines for patients on long-term parenteral support, ensuring they incorporate adequate choline levels to prevent liver injury and other related complications.
In addition to these impactful study results, Protara Therapeutics also shared encouraging financial updates. The company reported a significant 21% growth in cash and cash equivalents during the second quarter of 2024, alongside a decrease in current liabilities. This financial uptick has boosted Protara’s Quick Ratio to an impressive 15.86, indicating robust liquidity and financial health.
While Protara’s Quick Ratio may rank lower than nine other industry counterparts for the second quarter of 2024, the company has demonstrated a steady year-on-year improvement. Specifically, TARA’s cash and cash equivalents have seen a 6.18% increase on a trailing twelve months basis, elevating the trailing twelve months Quick Ratio to 13.91. This financial performance marks a significant upturn from the third quarter of 2023, where the ratio was previously 10.93, moving its overall ranking from 190 to 119 within the industry.
With the presentation of these robust THRIVE-1 findings and the ongoing financial strengthening, Protara Therapeutics continues to solidify its position as a key player in the evolving landscape of cancer and rare disease therapeutics. Their commitment to innovative research and sound financial management not only propels the company forward but also promises a brighter future for patients dependent on parenteral support.
Comments